

Docket No.: 12874-00013-US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Petra Lutter et al.

Application No.: National Phase of
PCT/EP2004/007890

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: REGULATORY T-CELLS CONTAINING
GALECTINS FOR THE THERAPY AND
DIAGNOSIS OF DISEASES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Applicant has not submitted copies of each cited U.S. patent and U.S. patent application as required by 37 CFR 1.98(a)(2)(i), amended October 2004, as the U.S. Patent and Trademark Office has waived this requirement for all U.S. patent applications. Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).


Application No.: National Phase of PCT/EP2004/007890

Dock

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 03-2775, under Order No. 12874-00013-US.

Dated: Jan. 13, 2006

Respectfully submitted,

By 
Liza D. Hohenschutz

Registration No.: 33,712
CONNOLLY BOVE LODGE & HUTZ LLP
Correspondence Customer Number: 23416
Attorney for Applicant

438787

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned 1564538
				Filing Date	Concurrently Herewith
				First Named Inventor	Petra Lutter
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	12874-00013-US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,242,807	09-07-1993	Ackerman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-98/15624	04-16-1998	Human Genome Sciences, Inc.		
	BB	WO-02/055728	07-18-2002	Mount Sinai Hospital		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	CA	Rabinovich, G. A. et al., "Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms", Cell Death and Differentiation, vol. 9, pp. 661-670 (2002).		
	CB	Joo, Hong-Gu et al., "Expression and function of galectin-3, a β -galactoside-binding protein in activated T lymphocytes", Journal of Leukocyte Biology, vol. 69, pp. 555-564 (2002).		
	CC	Abstract of papers, 223 rd ACS National Meeting, Orlando, FL, United States, April 7-11, 2002.		
	CD	Jonuleit, Helmut et al., "Identification and Functional Characterization of Human CD4 ⁺ CD25 ⁺ T Cells with Regulatory Properties Isolated from Peripheral Blood", J. Exp. Med., Vol. 193, Number 11, pp. 1285-1294 (June 4, 2001).		
	CE	Golightly, Linnie M. et al., "Charcot-Leyden crystal protein in the degranulation and recovery of activated basophils", Journal of Leukocyte Biology, vol. 51, pp. 386-392 (1992).		
	CF	Dvorak, Ann M. et al., "Ultrastructural Localization of Charcot-Leyden Crystal Protein (Lysophospholipase) to Intracytoplasmic Crystals in Tumor Cells of Primary Solid and Papillary Epithelial Neoplasm of the Pancreas", Laboratory Investigation, Vol. 62, No. 5, pp. 608-615 (1990).		
	CG	Dvorak, Ann M. et al., "Ultrastructural Localization of the Charcot-Leyden Crystal Protein (Lysophospholipase) to Granules and Intragranular Crystals in Mature Human Basophils", Laboratory Investigation, Vol. 60, No. 4, pp. 557-567 (1989).		
	CH	Piccirillo, Ciriaco A. et al., "Cutting Edge: Control of CD8 ⁺ T Cell Activation by CD4 ⁺ CD25 ⁺ Immunoregulatory Cells", Journal of Immunology, Vol. 167, No. 3, pp. 1137-1140 (2001).		
	CI	Seddon, Benedict et al., "The third function of the thymus", Immunology Today, Vol. 21, No. 2, pp. 95-99 (2000).		
	CJ	Dieckmann, Detlef et al., "Ex Vivo Isolation and Characterization of CD4 ⁺ CD25 ⁺ T Cells with Regulatory Properties from Human Blood", J. Exp. Med., Vol. 193, No. 11, pp. 1303-1310 (2001).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned 10/564588
				Filing Date	Concurrently Herewith
				First Named Inventor	Petra Lutter
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	12874-00013-US

CK	Ng, Wan Fai et al., "Human CD4+CD25+ cells: a naturally occurring population of regulator T cells", Blood, Vol. 98, No. 9, pp. 2736-2744 (2001).	
CL	Suri-Payer, Elizabeth et al., "CD4+CD25+ T Cells Inhibit Both the Induction and Effector Function of Autoreactive T Cells and Represent a Unique Lineage of Immunoregulatory Cells", Journal of Immunology, Vol. 160, No. 3, pp. 1212-1218 (1998).	
CM	Thornton, Angela M. et al., "CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production", The Journal of Experimental Medicine, Vol. 188, No. 2, pp. 287-296 (1998).	
CN	Database EMBL, "Homo sapiens Charcot-Leyden crystal protein mRNA, complete cds", Accession No. L01664, May 30, 2003.	
CO	Database UniProt, "Eosinophil lysophospholipase (EC 3.1.1.5) (Charcot-Leden crystal protein) (Lysolecithin acylhydrolase) (CLC) (Galactin-10)", Accession No. Q05315, June 1, 1994.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

438789

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--